Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Phreesia operates a SaaS platform for patient intake, registration, payment processing, and clinical data capture across 3,500+ healthcare provider organizations. The company monetizes through subscription fees tied to patient volume and payment processing revenue, with competitive advantages in workflow integration and regulatory compliance automation. Recent 60% stock decline reflects profitability concerns despite 18% revenue growth, as the company transitions from growth-at-all-costs to demonstrating operating leverage.
Phreesia charges healthcare providers subscription fees indexed to patient volumes, creating predictable recurring revenue with 95%+ retention rates. The platform captures payment processing economics when patients pay bills through the system. Pricing power stems from workflow stickiness—once integrated into practice management systems and EHR workflows, switching costs are high due to staff training, data migration complexity, and regulatory compliance requirements. The company benefits from network effects as more providers adopt the platform, making it more valuable for life sciences companies seeking patient engagement channels.
Net revenue retention rate (measures upsell/cross-sell success and patient volume growth at existing clients)
New healthcare provider client additions and average contract values (indicates market penetration velocity)
Payment processing revenue growth (signals patient payment adoption and healthcare consumerization trends)
Operating margin trajectory and path to profitability (investor focus shifted from growth-only to unit economics)
Healthcare IT spending trends and competitive win rates against Modernizing Medicine, Luma Health, Clearwave
EHR vendor vertical integration: Epic, Cerner/Oracle, and Athenahealth expanding native patient engagement modules could commoditize Phreesia's offerings and reduce TAM as integrated solutions gain traction
Regulatory changes to healthcare reimbursement models (shift to value-based care) could alter provider incentives for patient engagement technology investments
Data privacy regulations (HIPAA enforcement, state-level privacy laws) increase compliance costs and liability exposure for patient data platforms
Intense competition from well-funded rivals (Luma Health, Clearwave, Solutionreach) and point solutions offering lower-cost alternatives for specific workflows
Price compression risk as market matures and larger EHR vendors bundle patient engagement features at marginal cost
Customer concentration risk if large health systems negotiate volume discounts or multi-vendor strategies reduce wallet share
Cash burn trajectory: with near-zero operating cash flow and -14% operating margins, company must demonstrate path to profitability before liquidity concerns emerge despite current 2.44 current ratio
Equity dilution risk if additional capital raises needed to fund operations before achieving sustainable cash generation, particularly challenging given 60% stock decline reducing currency for equity financing
moderate - Revenue tied to patient visit volumes, which decline 5-10% during recessions as consumers defer elective procedures and routine care. However, healthcare is relatively defensive compared to discretionary sectors. Provider financial stress during downturns can accelerate adoption of revenue cycle automation tools (positive offset). Payment processing revenue more cyclical as patient out-of-pocket costs rise with high-deductible plans, potentially reducing collection rates.
Rising rates create dual pressure: (1) Higher discount rates compress valuation multiples for unprofitable SaaS companies, particularly acute for PHR given negative operating margins and 23x EV/EBITDA; (2) Healthcare provider capital spending becomes more constrained as financing costs rise, potentially slowing new client acquisition. However, minimal direct impact on operations given negligible debt (0.01 D/E ratio) and strong 2.44 current ratio providing liquidity buffer.
Low direct exposure. Company has minimal debt and operates asset-light SaaS model. Indirect exposure through healthcare provider client base—if hospitals/practices face credit stress or bankruptcies, could impact collections and churn rates. Payment processing revenue depends on patient ability to pay medical bills, which correlates with employment levels and consumer credit conditions.
growth - Company attracts investors focused on healthcare IT digitization trends and SaaS business models with high gross margins and recurring revenue. However, recent 60% decline reflects rotation away from unprofitable growth stocks as interest rates rose. Current valuation (1.5x P/S, down from 5-6x historically) may attract value-oriented investors if profitability inflection materializes. Requires tolerance for volatility and multi-year investment horizon to reach sustainable profitability.
high - Stock exhibits elevated volatility typical of small-cap ($700M market cap) unprofitable SaaS companies. Recent 60% twelve-month decline and -40% three-month performance demonstrate sensitivity to growth stock sentiment shifts and profitability concerns. Beta likely 1.5-2.0x relative to broader market. Quarterly earnings create significant price swings based on guidance revisions and margin trajectory updates.